Table of Content

1. Introduction to LAG-3 Targeting Therapies
1.1 LAG-3 As Therapeutic Target
1.2 LAG-3 Targeting Therapies - Mechanism Of Action
1.3 LAG-3 Targeting Approaches


2. Combination Strategies For LAG-3 Targeting Therapies


3. Global LAG-3 Targeting Therapy Market Scenario
3.1 Current Market Outlook
3.2 Future Market Outlook


4. LAG-3 Targeting Therapy Market Regional Analysis
4.1 US
4.2 EU
4.3 China
4.4 Australia
4.5 UK
4.6 Japan
4.7 Canada
4.8 South Korea


5. LAG-3 Targeting Therapy - Development Trends By Indication
5.1 Cancer
5.1.1 Lymphoma
5.1.2 Melanoma
5.1.3 Lung Cancer
5.1.4 Gastrointestinal Cancers
5.1.5 Head & Neck Cancer
5.2 Autoimmune & Inflammatory Diseases
5.3 Microbial Infections


6. Opdualag (Nivolumab & Relatlimab) - Overview, Pricing, Dosing & Sales Analysis
6.1 Overview & Patent Insight
6.2 Pricing & Dosing
6.3 Sales Insight


7. Global LAG-3 Targeting Therapies Clinical Trials Overview
7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status
7.6 Patient Segment


8. Global LAG3 Targeting Therapies clinical Trials Insight By Company, Country, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase II/III
8.7 Phase III


9. Marketed LAG-3 Inhibitor Clinical Insight


10. Global LAG-3 Targeting Therapy Market Dynamics
10.1 Market Drivers
10.2 Market Challenges


11. Competitive Landscape
11.1 ABL Bio
11.2 Agenus
11.3 Akeso Biopharma
11.4 Bristol-Myers Squibb
11.5 EpimAb Biotherapeutics
11.6 F-star Therapeutics
11.7 Immutep
11.8 Innovent Biologics
11.9 Shanghai Henlius Biotech
11.10 Y-Biologics



List of Figures

Figure 1-1: LAG-3/MHC Class II Signaling Pathway
Figure 1-2: LAG-3 Targeted Therapy Landscape - Milestones
Figure 1-3: LAG-3 Inhibitor – Mechanism Of Action
Figure 1-4: LAG-3 Agonist – Mechanism Of Action
Figure 1-5: LAG-3 Depletion – Mechanism Of Action
Figure 1-6: Bispecific Antibodies - Binding Efficacy

Figure 2-1: Overview to LAG-3 Combinations

Figure 3-1: Global – LAG 3 Targeting Therapy Market Value (US$ Million), 2022-2024
Figure 3-2: Global – LAG 3 Targeting Therapy Market Value By Region (US$ Million), 2024
Figure 3-3: Global – LAG 3 Targeting Therapy Market Value By Region (%), 2024
Figure 3-4: Global – Quarterly LAG 3 Targeting Therapy Market Value (US$ Million), 2024
Figure 3-5: Global – LAG 3 Targeting Therapy Market Forecast (US$ Million), 2025 - 2030
Figure 3-6: Global LAG-3 Targeting Therapy Market - Future Outlook

Figure 4-1: EU - Research Institutes & Hospitals Conducting LAG-3 Therapy Clinical Trials

Figure 5-1: RELATIVITY-069 Phase 1/2 (NCT05255601) Study – Initiation & Completion Year
Figure 5-2: AK129-102 Phase 1/2 (NCT06642792) Study – Initiation & Completion Year
Figure 5-3: R3767-ONC-2011 Phase 3 (NCT05352672) Study – Initiation & Completion Year
Figure 5-4: R3767-ONC-2055 Phase 3 (NCT05352672) Study – Initiation & Completion Year
Figure 5-5: INCAGN 2385-201 Phase 1/2 (NCT04370704) Study – Initiation & Completion Year
Figure 5-6: R3767-ONC-2235 Phase 2/3 (NCT05785767) Study – Initiation & Completion Year
Figure 5-7: R3767-ONC-2236 Phase 2/3 (NCT05800015) Study – Initiation & Completion Year
Figure 5-8: R2810-ONC-1866 Phase 2 (NCT03916627) Study – Initiation & Completion Year
Figure 5-9: R2810-ONC-2266 Phase 2 (NCT06161441) Study – Initiation & Completion Year
Figure 5-10: RELATIVITY-104 Phase 2 (NCT04623775) Study – Initiation & Completion Year
Figure 5-11: RELATIVITY-1093 Phase 3 (NCT06561386) Study – Initiation & Completion Year
Figure 5-12: J23155 Phase 2 (NCT06205836) Study – Initiation & Completion Year
Figure 5-13: J1714 Phase 1b (NCT03044613) Study – Initiation & Completion Year
Figure 5-14: RELATIVITY-123 Phase 3 (NCT05328908) Study – Initiation & Completion Year
Figure 5-15: NP41300 Phase 1/2 (NCT04140500) Study – Initiation & Completion Year
Figure 5-16: LBL-007-CN-003 Phase 1b/2 (NCT05102006) Study – Initiation & Completion Year
Figure 5-17: HCC 18-139 Phase 2 (NCT04080804) Study – Initiation & Completion Year
Figure 5-18: IMP761-P001 Phase 1 (NCT06637865) Study – Initiation & Completion Year

Figure 6-1: Opdualag – Approval Year by Region
Figure 6-2: Opdualag - Estimated Minimum Market Exclusivity Year By Region
Figure 6-3: US – Cost Per Unit & Supply Of Opdualag (US$), April’2025
Figure 6-4: Cost Per Unit & Supply Of Opdualag (US$), April’2025
Figure 6-5: Global – Opdualag Annual Sales (US$ Million), 2022-2024
Figure 6-6: Global – Opdualag Sales (US$ Million), Q1-Q4’2024
Figure 6-7: Opdualag – US v/s ROW Sales (US$ Million), 2024
Figure 6-8: Global – Opdualag Sales (US$ Million), 2024
Figure 6-9: US – Opdualag Sales (US$ Million), 2022-2024
Figure 6-10: US – Opdualag Sales (US$ Million), Q1-Q4’2024
Figure 6-11: ROW – Opdualag Sales (US$ Million), 2022-2024
Figure 6-12: ROW – Opdualag Sales (US$ Million), Q1-Q4’2024

Figure 7-1: Global – LAG-3 Inhibitor Clinical Trials By Phase (Numbers), 2025 - 2030
Figure 7-2: Global – LAG-3 Inhibitor Clinical Trials By Country (Numbers), 2025 - 2030
Figure 7-3: Global – LAG-3 Inhibitor Clinical Trials By Company (Numbers), 2025 - 2030
Figure 7-4: Global – LAG-3 Inhibitor Clinical Trials By Indication (Numbers), 2025 - 2030
Figure 7-5: Global – LAG-3 Inhibitor Clinical Trials By Priority Status (Numbers), 2025 - 2030
Figure 7-6: Global – LAG-3 Inhibitor Clinical Trials By Patient Segment (Numbers), 2025 - 2030

Figure 10-1: Global LAG-3 Targeting Therapy Market - Drivers & Opportunities
Figure 10-2: Global LAG-3 Targeting Therapy Market - Challenges & Restraints

List of Tables

Table 2-1: Ongoing Preclinical & Clinical Trials For Combination of LAG-3 inhibitors, April’2025

Table 4-1: US - Ongoing Clinical Trials For LAG-3 Targeting Therapies, April’2025
Table 4-2: China - Ongoing Clinical Trials For LAG-3 Targeting Therapies, April’2025
Table 4-3: Immutep – Active Patents By Region

Table 5-1: Melanoma – Some Ongoing Clinical Trials For LAG-3 Inhibitors, April’2025

Table 6-1: Opdualag - Maximum Infusion Volumes & Concentration Ranges By Patient Group 1
Table 6-2: Opdualag - Recommended Dosage Modifications For Adverse Reactions